A Single-Center, Randomized, Double-Blind, Two-Way Crossover Study to Evaluate Whether a Single-Dose Administration of Crushed and Whole EMBEDA Induces Clinical Opiate Withdrawal Signs and Symptoms in Opioid-Dependent Patients With Chronic, Non-Cancer Pain Who Are Stabilized on EMBEDA.

Trial Profile

A Single-Center, Randomized, Double-Blind, Two-Way Crossover Study to Evaluate Whether a Single-Dose Administration of Crushed and Whole EMBEDA Induces Clinical Opiate Withdrawal Signs and Symptoms in Opioid-Dependent Patients With Chronic, Non-Cancer Pain Who Are Stabilized on EMBEDA.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2012

At a glance

  • Drugs Morphine/naltrexone (Primary)
  • Indications Pain
  • Focus Adverse reactions
  • Sponsors Alpharma
  • Most Recent Events

    • 22 Dec 2011 Results published in a Pfizer media release.
    • 29 Nov 2011 Planned number of patients changed from 80 to 14 as reported by ClinicalTrials.gov.
    • 04 Apr 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top